No profile data available.
International Stem Cell Corporation (ISCO) is a healthcare company in the biological analysis equipment industry, based in San Diego, United States, with about 33 full-time employees.
It reported revenue of $9.10 million for fiscal year 2025, up 0.2% from fiscal year 2024, and net income of -$418,000. In Q1 2026 (the quarter ended March 31, 2026) revenue was $2.32 million, up 8.7% from a year before. Its largest business segment, Biomedical Market, brought in 93% of segment revenue in fiscal year 2025; United States was the largest region with 86%. Its market capitalization was $2.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
International Stem Cell reported $9.10 million in revenue for fiscal year 2025, up 0.2% from $9.09 million in fiscal year 2024. In Q1 2026 revenue was $2.32 million.
Biomedical Market, with $8.50 million or 93% of segment revenue in fiscal year 2025. Next: Anti-Aging Market (7%).
United States: 86% of revenue by region in fiscal year 2025, followed by Asia (8%).
$2.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Bionano Genomics, Inc. (BNGO), Advanced Biomed Inc. (ADVB), iSpecimen Inc. (ISPC), InVitro International, Inc. (IVRO).